Advertisement

Surgery Today

, Volume 41, Issue 4, pp 510–513 | Cite as

Preoperative elevation of serum C-reactive protein as an independent prognostic indicator for gastric cancer

  • Tadahiro Nozoe
  • Tomohiro Iguchi
  • Eisuke Adachi
  • Akito Matsukuma
  • Takahiro Ezaki
Original Article

Abstract

Purpose

Preoperative elevation of serum C-reactive protein (CRP) is a prognostic indicator for some malignant tumors. We investigated the clinicopathologic importance of an elevated preoperative serum CRP value in gastric carcinoma patients.

Methods

We studied the relationship between the preoperative serum CRP value and clinicopathologic characteristics in 204 patients who underwent curative resection of gastric carcinoma.

Results

The patients with preoperative CRP elevation had significantly poorer survival than those without CRP elevation (P < 0.0001). According to multivariate analysis, the factors independently associated with an unfavorable prognosis were a high preoperative CRP value (P = 0.024), lymphatic invasion (P = 0.017) and advanced tumor stage (P = 0.016).

Conclusion

Preoperative serum CRP elevation can be an independent prognostic indicator in patients with gastric carcinoma.

Key words

Gastric carcinoma C-reactive protein Curative resection Prognostic indicator 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zimmerman MA, Selzman CH, Cothren C, Sorensen AC, Raeburn CD, Harken AH. Diagnostic implications of C-reactive protein. Arch Surg 2003;138:220–224.PubMedCrossRefGoogle Scholar
  2. 2.
    Rashid SA, O’Quigley J, Axon AT, Cooper EH. Plasma protein profiles and prognosis in gastric cancer. Br J Cancer 1982;45:390–394.PubMedCrossRefGoogle Scholar
  3. 3.
    Shiu YC, Lin JK, Huang CJ, Jiang JK, Wang LW, Huang HC, et al. Is C-reactive protein a prognostic factor of colorectal cancer? Dis Colon Rectum 2008;51:443–449.PubMedCrossRefGoogle Scholar
  4. 4.
    Nozoe T, Mori E, Takahashi I, Ezaki T. Preoperative elevation of serum C-reactive protein as an independent prognostic indicator of colorectal carcinoma. Surg Today 2008;38:597–602.PubMedCrossRefGoogle Scholar
  5. 5.
    Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998;176:335–338.PubMedCrossRefGoogle Scholar
  6. 6.
    Deans DA, Wigmore SJ, de Beaux AC, Paterson-Brown S, Garden OJ, Fearon KC. Clinical prognostic scoring system to aid decisionmaking in gastro-oesophageal cancer. Br J Surg 2007;94:1501–1508.PubMedCrossRefGoogle Scholar
  7. 7.
    Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001;182:197–201.PubMedCrossRefGoogle Scholar
  8. 8.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998;1:10–24.Google Scholar
  9. 9.
    Senju O, Takagi Y, Uzawa R, Iwasaki Y, Suzuki T. A new immunoquantitative method by latex agglutination — application for the determination of serum C-reactive protein (CRP) and its clinical significance. J Clin Lab Immunol 1986;19:99–103.PubMedGoogle Scholar
  10. 10.
    Du Clos TW. Function of C-reactive protein. Ann Med 2000;32:274–278.PubMedCrossRefGoogle Scholar
  11. 11.
    Nozoe T, Korenaga D, Futatsugi M, Saeki H, Maehara Y, Sugimachi K. Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus — significance as a tumor marker. Cancer Lett 2003;192:89–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, et al. Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 2007;27:3001–3004.PubMedGoogle Scholar
  13. 13.
    Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, et al. C-reactive protein as a prognostic marker for men with androgenindependent prostate cancer: results from the ASCENT trial. Cancer 2008;112:2377–2383.PubMedCrossRefGoogle Scholar
  14. 14.
    Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008;14:710–714.PubMedCrossRefGoogle Scholar
  15. 15.
    Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 2008;14:428–434.PubMedCrossRefGoogle Scholar
  16. 16.
    Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005;8:124–131.PubMedCrossRefGoogle Scholar
  17. 17.
    Forones NM, Mandowsky SV, Lourenço LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology 2001;48: 1199–1201.PubMedGoogle Scholar
  18. 18.
    Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, et al. Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 2008;46:359–364.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Tadahiro Nozoe
    • 1
  • Tomohiro Iguchi
    • 1
  • Eisuke Adachi
    • 1
  • Akito Matsukuma
    • 1
  • Takahiro Ezaki
    • 1
  1. 1.Department of SurgeryFukuoka Higashi Medical CenterKogaJapan

Personalised recommendations